Lowering Hep C Viral Load in Non Responders
September 19, 2007
AFX News Limited
Roche’s US partner Pharmasset says hepatitis C trial drug decreases virus level
09.10.07, 10:37 AM ET
ZURICH (Thomson Financial) – Roche Holdings AG’s US partner Pharmasset Inc said hepatitis C trial drug R7128 successfully lowered the level of the virus in patients who failed to respond to interferon therapy.
The phase I clinical study was carried out for 14 days on 40 patients, with R7128 showing ‘potent antiviral activity’ as well as being safe and well tolerated, Pharmasset (nasdaq: VRUS – news – people ) said. Dosages used in the study were 750 mg or 1500 mg.
New Jersey based Pharmasset is collaborating with Roche to develop the drug, and based on the results of the trial will start a 28-day study of R7128 in combination with interferon Pegasys plus Copegus.
R7128 is classed as a nucleoside polymerase inhibitor, a new generation of antivirals being developed to treat hepatitis C patients.
Body Shop Founder's Legacy
HCV's Gene Unraveling Secret Discovered